Head-To-Head Review: Eton Pharmaceuticals (NASDAQ:ETON) versus Fortress Biotech (NASDAQ:FBIO)

Eton Pharmaceuticals (NASDAQ:ETON) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Risk & Volatility

Eton Pharmaceuticals has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Earnings & Valuation

This table compares Eton Pharmaceuticals and Fortress Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95 million	21.15	-$4.60 million	$0.38	155.73
Fortress Biotech	$63.26 million	1.14	$6.82 million	$2.64	0.82

Fortress Biotech has lower revenue, but higher earnings than Eton Pharmaceuticals. Fortress Biotech is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Eton Pharmaceuticals and Fortress Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Fortress Biotech	163.32%	83.47%	42.98%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Eton Pharmaceuticals and Fortress Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	0	2	4	0	2.67
Fortress Biotech	1	1	2	0	2.25

Eton Pharmaceuticals presently has a consensus target price of $67.50, suggesting a potential upside of 14.07%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 685.22%. Given Fortress Biotech’s higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Eton Pharmaceuticals.

Summary

Fortress Biotech beats Eton Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

About Fortress Biotech

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company’s early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.